Drug Profile
IMMU 140
Alternative Names: IMMU-140Latest Information Update: 26 Sep 2023
Price :
$50
*
At a glance
- Originator Immunomedics
- Class Antineoplastics; Camptothecins; Drug conjugates; Immunoconjugates; Monoclonal antibodies
- Mechanism of Action DNA topoisomerase I inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Haematological malignancies; Solid tumours
Most Recent Events
- 26 Sep 2023 Discontinued - Preclinical for Haematological malignancies in USA (Parenteral)
- 26 Sep 2023 Discontinued - Preclinical for Solid tumours in USA (Parenteral)
- 28 Feb 2021 No recent reports of development identified for preclinical development in Solid-tumours in USA (Parenteral)